Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Pear Therapeutics

201 Mission Street
San Francisco, CA 94105
United States
Website Company Summary Management Team
Management

General Management: Antoun Nabhan (10/31/2017) ; David Amor (8/31/2017) ; Beth Rogozinski (1/31/2014) ; Yuri Maricich (10/31/2017)
Finance: Christopher Guiffre (12/31/2017)
Technology: Davina Pallone (3/31/2017) ; Jeremy Gilbert (2/28/2018) ; Walter Greenleaf (4/30/2014)
Sales/Marketing: Robin Jolliffe
Business Development: Alex Waldron
HR: Jeff Kagy
General Counsel/Legal: Ronan O’Brien
Former Employees: Andrew Nielsen Ian McFarland
Board

Company

Business description: Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics. The company integrates clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear’s lead product, reSET®, is an FDA-cleared 12-week interval prescription therapy for Substance Use Disorder (SUD) to be used as an adjunct to standard, outpatient treatment. Pear’s product development pipeline includes reSET-O™ for opioid use disorder (OUD) and additional prescription digital therapeutics in schizophrenia (Thrive™), combat post-traumatic stress disorder (reCALL™), general anxiety disorder (reVIVE™), pain, major depressive disorder, and insomnia.
Capital

Rounds: 4
Recent Fundings: Jan 2019   Jan 2018
Capital raised: 135.25M
Last Round: 64.0M
Ownership: Private  
VCs include: 5AM Ventures Arboretum Ventures Jazz Venture Partners ;  Bridge Builder’s Collaborative
Corporate investors: Novartis ;  EDBI
Private equity: Temasek

Last Tweets


 

Last Mentions


Overview
Record updated: Jan 2019
Sector: Medical
Headcount: 101-150 as of Dec 2018
Rounds: 4
Recent Fundings: Jan 2019   Jan 2018
Capital Raised: 135.25M
Last Round: 64.0M
Ownership: Private